EBNA-2 upregulation of Epstein-Barr virus latency promoters and the cellular CD23 promoter utilizes a common targeting intermediate, CBF1 - PubMed (original) (raw)
Comparative Study
EBNA-2 upregulation of Epstein-Barr virus latency promoters and the cellular CD23 promoter utilizes a common targeting intermediate, CBF1
P D Ling et al. J Virol. 1994 Sep.
Abstract
The EBNA-2 protein is essential for the establishment of a latent Epstein-Barr virus (EBV) infection and for B-cell immortalization. EBNA-2 functions as a transcriptional activator that modulates viral latency gene expression as well as the expression of cellular genes, including CD23. We recently demonstrated that EBNA-2 transactivation of the EBV latency C promoter (Cp) is dependent on an interaction with a cellular DNA-binding protein, CBF1, for promoter targeting. To determine whether targeting via CBF1 is a common mechanism for EBNA-2-mediated transactivation, we have examined the requirements for activation of the cellular CD23 promoter. Binding of CBF1 to a 192-bp mapped EBNA-2-responsive region located at position -85 bp to -277 bp upstream of the CD23 promoter was detected in electrophoretic mobility shift assays. The identity of the bound protein as CBF1 was established by showing that the bound complex was competed for by the CBF1 binding site from the EBV Cp, that the bound protein could be supershifted with a bacterially expressed fusion protein' containing amino acids 252 to 425 of EBNA-2 but was unable to interact with a non-CBF1-binding EBNA-2 mutant (WW323SR), and that in UV cross-linking experiments, the Cp CBF1 binding site and the CD23 probe bound proteins of the same size. The requirement for interaction with CBF1 was demonstrated in a transient cotransfection assay in which the multimerized 192-bp CD23 response region was transactivated by wild-type EBNA-2 but not by the WW323SR mutant. Reporter constructions carrying multimerized copies of the 192-bp CD23 response region or multimers of the CBF1 binding site from the CD23 promoter were significantly less responsive to EBNA-2 transactivation than equivalent constructions carrying a multimerized region from the Cp or multimers of the CBF1 binding site from the Cp. Direct binding and competition assays using 30-mer oligonucleotide probes representing the individual CBF1 binding sites indicated that CBF1 bound less efficiently to the CD23 promoter and the EBV LMP-1 promoter sites than to the Cp site. To investigate the basis for this difference, we synthesized a series of oligonucleotides carrying mutations across the CBF1 binding site and used these as competitors in electrophoretic mobility shift assays. The competition experiments indicated that a central core sequence, GTGGGAA, common to all known EBNA-2-responsive elements, is crucial for CBF1 binding. Flanking sequences on either side of this core influence the affinity for CBF1.(ABSTRACT TRUNCATED AT 400 WORDS)
Similar articles
- The Epstein-Barr virus immortalizing protein EBNA-2 is targeted to DNA by a cellular enhancer-binding protein.
Ling PD, Rawlins DR, Hayward SD. Ling PD, et al. Proc Natl Acad Sci U S A. 1993 Oct 15;90(20):9237-41. doi: 10.1073/pnas.90.20.9237. Proc Natl Acad Sci U S A. 1993. PMID: 8415684 Free PMC article. - Characterization of the CBF2 binding site within the Epstein-Barr virus latency C promoter and its role in modulating EBNA2-mediated transactivation.
Fuentes-Pananá EM, Ling PD. Fuentes-Pananá EM, et al. J Virol. 1998 Jan;72(1):693-700. doi: 10.1128/JVI.72.1.693-700.1998. J Virol. 1998. PMID: 9420275 Free PMC article. - Epstein-Barr virus EBNA3C represses Cp, the major promoter for EBNA expression, but has no effect on the promoter of the cell gene CD21.
Radkov SA, Bain M, Farrell PJ, West M, Rowe M, Allday MJ. Radkov SA, et al. J Virol. 1997 Nov;71(11):8552-62. doi: 10.1128/JVI.71.11.8552-8562.1997. J Virol. 1997. PMID: 9343213 Free PMC article. - Immortalizing genes of Epstein-Barr virus.
Middleton T, Gahn TA, Martin JM, Sugden B. Middleton T, et al. Adv Virus Res. 1991;40:19-55. doi: 10.1016/s0065-3527(08)60276-6. Adv Virus Res. 1991. PMID: 1659776 Review. - Impact of EBV essential nuclear protein EBNA-3C on B-cell proliferation and apoptosis.
Saha A, Robertson ES. Saha A, et al. Future Microbiol. 2013 Mar;8(3):323-52. doi: 10.2217/fmb.12.147. Future Microbiol. 2013. PMID: 23464371 Free PMC article. Review.
Cited by
- Multifaceted roles for STAT3 in gammaherpesvirus latency revealed through in vivo B cell knockout models.
Hogan CH, Owens SM, Reynoso GV, Liao Y, Meyer TJ, Zelazowska MA, Liu B, Li X, Grosskopf AK, Khairallah C, Kirillov V, Reich NC, Sheridan BS, McBride KM, Gewurz BE, Hickman HD, Forrest JC, Krug LT. Hogan CH, et al. mBio. 2024 Feb 14;15(2):e0299823. doi: 10.1128/mbio.02998-23. Epub 2024 Jan 3. mBio. 2024. PMID: 38170993 Free PMC article. - Treatment Options for Epstein-Barr Virus-Related Disorders of the Central Nervous System.
Andersen O, Ernberg I, Hedström AK. Andersen O, et al. Infect Drug Resist. 2023 Jul 13;16:4599-4620. doi: 10.2147/IDR.S375624. eCollection 2023. Infect Drug Resist. 2023. PMID: 37465179 Free PMC article. Review. - Molecular Basis of Epstein-Barr Virus Latency Establishment and Lytic Reactivation.
Murata T, Sugimoto A, Inagaki T, Yanagi Y, Watanabe T, Sato Y, Kimura H. Murata T, et al. Viruses. 2021 Nov 23;13(12):2344. doi: 10.3390/v13122344. Viruses. 2021. PMID: 34960613 Free PMC article. Review. - MYC activation and BCL2L11 silencing by a tumour virus through the large-scale reconfiguration of enhancer-promoter hubs.
Wood CD, Veenstra H, Khasnis S, Gunnell A, Webb HM, Shannon-Lowe C, Andrews S, Osborne CS, West MJ. Wood CD, et al. Elife. 2016 Aug 4;5:e18270. doi: 10.7554/eLife.18270. Elife. 2016. PMID: 27490482 Free PMC article. - The EBNA-2 N-Terminal Transactivation Domain Folds into a Dimeric Structure Required for Target Gene Activation.
Friberg A, Thumann S, Hennig J, Zou P, Nössner E, Ling PD, Sattler M, Kempkes B. Friberg A, et al. PLoS Pathog. 2015 May 29;11(5):e1004910. doi: 10.1371/journal.ppat.1004910. eCollection 2015 May. PLoS Pathog. 2015. PMID: 26024477 Free PMC article.
References
- Proc Natl Acad Sci U S A. 1987 Nov;84(22):8060-4 - PubMed
- J Virol. 1987 Nov;61(11):3424-30 - PubMed
- J Virol. 1991 Dec;65(12):6765-71 - PubMed
- J Virol. 1992 Jan;66(1):496-504 - PubMed
- Genes Dev. 1991 Dec;5(12B):2555-66 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous